Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab-dlle) has met its primary endpoint at a planned interim ...

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

DNI Tulsi Gabbard said Thursday that the assassination files of Martin Luther King Jr. and Robert F. Kennedy would be released in "the next few days." ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

WASHINGTON, D.C. - The Lawyer’s Committee for Civil Rights Under Law has filed a brief here April on behalf of the Southern ...

No new safety signals were identified for Imfinzi in patients with LS-SCLC. The proportion of patients with adverse events leading to discontinuation of study treatment was 16.4% in the Imfinzi arm.

King family opposes release of classified documents on King's assassination, citing privacy concerns and potential harm to ...